The American Journal of Managed Care
Schwartz et al.
Colorectal cancer screening involves balancing immediate harms with longer-term benefits; electronic medical record decision support may facilitate personalized benefit/harm assessment.
Mitigating cost increases through preemptive care and clinical efficacy to reduce the disease burden of clinically at-risk patients.
Sharp et al.
Acute sinusitis is a common acute illness and offers an opportunity to eliminate low-value care. The authors describe current practices, comparing primary care, urgent care, and the emergency department.
The American Journal of Pharmacy Benefits
Sow et al.
E-prescribing adoption has increased dramatically over the past decade. This study provides empirical evidence that utilization among adopters continues to increase, suggesting application “stickiness.”
Eisenberg and Butterfield
Incorporating patient-related sociodemographic factors into performance measurement systems is essential for providing an accurate assessment of the quality of care delivered.
The American Journal of Accountable Care
Chernew et al.
Arkansas has implemented multi-payer payment reform incorporating both episodic and Patient-Centered Medical Home models. Early perceptions of a sample of stakeholders were largely positive to date.
Evidence provided by a study published in The Lancet Oncology affirms that oral contraceptives provide long-term protection against endometrial cancer.
An article published in JAMA Oncology underscores the need for efforts to improve quality of life for cancer patients.
The study presented at the ADA Scientific Sessions found that raising out-of-pocket costs for diabetics with Medicare could reduce adherence and ultimately raise healthcare spending.
Years of work has moved technology to the point of large-scale testing that is required before FDA approval and commercialization.
A leading voice on diabetes care asks why Medicare still will not cover CGM technology.
August 28, 2015 | Mary K. Caffrey
Both ExpressScripts and CVS Health say the new class of cholesterol-fighting drugs will be generally unavailable until their P&T committees complete evaluations, and negotiations for discounts or exclusive deals occur.
August 28, 2015 | Surabhi Dangi-Garimella, PhD
The study published in JNCI has identified CES2 expression as a predictor of response to FOLFIRINOX.
August 28, 2015 | Laura Joszt
In the second quarter of 2015 the healthcare spending growth rate was 5.9%, a decline from 6.6% in the first quarter of the year, but the health spending growth rate is still 2 percentage points higher than rates experienced between 2009 and 2013.
August 28, 2015 | Laura Joszt
With 1 biosimilar already approved in the US, the FDA has finally released draft guidelines for naming these new products.
August 28, 2015 |
While the shift to cancer becoming more of a chronic disease does not have a huge change on the approach of the payer, there are some new challenges to address, said Jennifer Malin, MD, medical director for oncology at Anthem.